About Strongbridge Biopharma
Strongbridge Biopharma is a company based in Feasterville Trevose (United States) founded in 1996 by Per Marin was acquired by Xeris Pharmaceuticals in May 2021.. Strongbridge Biopharma operates in a competitive market with competitors including MBX Biosciences, Amolyt Pharma, OMass Therapeutics, Spruce and Spruce Biosciences, among others.
- Headquarter Feasterville Trevose, United States
- Founders Per Marin
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Cortendo Invest Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$3 M (USD), Post-IPO
Jul 17, 2017
-
Investors
Xeris Pharmaceuticals
& 11 more
-
Employee Count
Employee Count
-
Acquired by
Xeris Pharmaceuticals
(May 24, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
30 people
Software Development Team
12 people
Product Management Team
11 people
Operations Team
8 people
Finance and Accounting
7 people
Sales and Marketing
6 people
Legal and Compliance
5 people
Senior Team
4 people
Unlock access to complete
Funding Insights of Strongbridge Biopharma
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $3.0M
-
First Round
First Round
(30 Oct 2014)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2017 | Amount | Post-IPO - Strongbridge Biopharma | Valuation |
investors |
|
| Dec, 2016 | Amount | Post-IPO - Strongbridge Biopharma | Valuation |
investors |
|
| Aug, 2015 | Amount | Post-IPO - Strongbridge Biopharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Strongbridge Biopharma
Strongbridge Biopharma has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Xeris Pharmaceuticals, Storebrand and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Strongbridge Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Strongbridge Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Strongbridge Biopharma Comparisons
Competitors of Strongbridge Biopharma
Strongbridge Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MBX Biosciences, Amolyt Pharma, OMass Therapeutics, Spruce and Spruce Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| domain | founded_year | HQ Location |
Spruce is engaged in providing real estate closing services.
|
|
| domain | founded_year | HQ Location |
Rare HPA axis diseases are targeted by Spruce Biosciences' therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for chronic diseases are developed via cell engineering platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Strongbridge Biopharma
Frequently Asked Questions about Strongbridge Biopharma
When was Strongbridge Biopharma founded?
Strongbridge Biopharma was founded in 1996 and raised its 1st funding round 18 years after it was founded.
Where is Strongbridge Biopharma located?
Strongbridge Biopharma is headquartered in Feasterville Trevose, United States. It is registered at Feasterville Trevose, Pennsylvania, United States.
What does Strongbridge Biopharma do?
Strongbridge Biopharma was founded in 1996 by Per Marin and is headquartered in Feasterville Trevose, United States. Focus is placed on the biotechnology sector, where therapies for rare endocrine disorders are developed. Operations center on cortisol synthesis inhibitors like COR-003 levoketoconazole for endogenous Cushings syndrome, somatostatin analogs such as COR-005 for acromegaly, and KEVEYIS for periodic paralysis. Clinical advancements and regulatory approvals are pursued to address unmet needs in endocrinology.
Who are the top competitors of Strongbridge Biopharma?
Strongbridge Biopharma's top competitors include MBX Biosciences, OMass Therapeutics and Spruce.
Who are Strongbridge Biopharma's investors?
Strongbridge Biopharma has 12 investors. Key investors include Xeris Pharmaceuticals, Storebrand, RA Capital, CRG, and Vivo Capital.